CWP 232291

Drug Profile

CWP 232291

Alternative Names: CWP 291; CWP232291

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator JW Pharmaceutical
  • Class Antineoplastics; Peptidomimetics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Multiple myeloma
  • Preclinical Solid tumours

Most Recent Events

  • 13 Feb 2017 JW Pharmaceutical plans a phase Ib trial for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in South Korea and USA (NCT03055286)
  • 03 Dec 2016 Interim efficacy, pharmacodynamics and adverse event data from a phase I trial in Multiple Myeloma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 12 Aug 2016 Phase-I development is ongoing for Acute myeloid leukaemia (Second-line therapy or greater) in USA and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top